超声引导下经宫颈消融治疗子宫平滑肌瘤
这项前瞻性、多中心、单臂干预试验评估经宫颈消融治疗有症状子宫平滑肌瘤的12个月安全性和有效性,在美国和墨西哥纳入147例患者。12个月时64.8%患者月经出血量减少50%及以上,99.3%患者免于再次手术,无器械相关不良事件。
要点
- 12个月时64.8%患者月经出血量减少≥50%,99.3%患者未再接受手术干预
- 12个月时症状严重程度和健康相关生活质量分别平均改善32.1分和43.7分
- 无器械相关不良事件,96.3%患者报告症状改善,97%对治疗表示满意
核心结论
- 经宫颈消融与平滑肌瘤症状显著减轻相关,12个月内无器械相关不良事件且再次手术干预率低,显示其有望通过保留子宫、无切口方式安全有效地治疗所有非带蒂型平滑肌瘤。
研究设计与样本
- 前瞻性、多中心、单臂干预试验,每例患者对1-10个直径1-5 cm的平滑肌瘤行经宫颈消融,治疗包括所有非带蒂型;在美国和墨西哥共纳入并治疗147例患者,12个月评估采用全分析集N=143。
主要发现
- 12个月时64.8%患者(95%CI 56.3-72.6%)月经出血量减少50%及以上;99.3%患者(95%CI 95.1-99.9%)免于再次手术干预;95.1%患者12个月时月经出血量减少。
- 月经失血图评分均值在3、6、12个月分别下降38.9%、48.4%、51.1%(P<.001)。
- 12个月时症状严重程度和健康相关生活质量分别平均改善32.1分和43.7分(均P<.001);每例患者平滑肌瘤最大体积平均缩小62.4%(P<.001)。
- 超过半数患者1天内恢复正常活动,96.3%患者12个月时报告症状改善,97%患者12个月时对治疗表示满意;无器械相关不良事件。
临床怎么用
- 作者认为经宫颈消融有望通过保留子宫、无切口方式安全有效地治疗所有非带蒂型平滑肌瘤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the 12-month safety and effectiveness of transcervical ablation for the treatment of symptomatic uterine leiomyomas. METHODS: In this prospective, multicenter, single-arm interventional trial, transcervical ablation was performed on 1-10 leiomyomas per patient with leiomyoma diameters ranging from 1 to 5 cm. Treated leiomyomas included all nonpedunculated types. Coprimary endpoints assessed at 12 months were reduction in menstrual blood loss and absence of surgical reintervention. Additional assessments included symptom severity, quality of life, patient satisfaction, reductions in uterine and leiomyoma volumes, and safety. RESULTS: One hundred forty-seven patients were enrolled and treated in the United States and Mexico. The study met its coprimary endpoints at 12 months (N=143; full analysis set), because 64.8% of patients (95% CI 56.3-72.6%) experienced 50% or greater reduction in menstrual bleeding and 99.3% of patients (95% CI 95.1-99.9%) were free from surgical reintervention. The mean pictorial blood loss assessment chart score decreased by 38.9%, 48.4%, and 51.1% at 3, 6, and 12 months, respectively (P<.001), and 95.1% of patients experienced a reduction in menstrual bleeding at 12 months. There were significant mean improvements in symptom severity and health-related quality of life of 32.1 points and 43.7 points, respectively, at 12 months (all P<.001). Mean maximal leiomyoma volume reduction per patient was 62.4% (P<.001). More than half of patients returned to normal activity within 1 day, 96.3% of patients reported symptom improvement at 12 months, and 97% expressed satisfaction with the treatment at 12 months. There were no device-related adverse events. CONCLUSION: Transcervical ablation was associated with a significant reduction in leiomyoma symptoms with no device-related adverse events and a low surgical reintervention rate through 12 months, demonstrating its potential to safely and effectively treat all nonpedunculated leiomyoma types through a uterus-conserving, incisionless approach. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02228174. FUNDING SOURCE: Supported by Gynesonics, Inc.
引用
- Chudnoff S, Guido R, Roy K, et al. Ultrasound-Guided Transcervical Ablation of Uterine Leiomyomas. Obstet Gynecol. 2019. PMID: 30531573. doi:10.1097/AOG.0000000000003032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。